Acucela, Otsuka Pharmaceutical deal

Acucela will receive an exclusive opt-in right to co-develop and co-promote Otsuka's OPA-6566 in the U.S. for ophthalmic indications. Acucela will conduct early clinical development in the U.S. for th...